| answer text |
<p>As with all vaccines and medicines, the Medicines and Healthcare products Regulatory
Agency (MHRA) closely monitors the safety of the human papillomavirus (HPV) vaccine.
The MHRA takes advice from the Government's independent expert advisory body, the
Commission on Human Medicines (CHM), when evaluating the risks and benefits of medicines
and vaccines.</p><p> </p><p>The MHRA takes account of all available sources of safety
data, including reports of suspected side effects submitted through the Yellow Card
Scheme. A Yellow Card report is not proof of a side effect occurring, but a suspicion
by the reporter that the vaccine may have been the cause. Such reports are kept under
continual review.</p><p> </p><p>Since 2008, at least three million girls have been
vaccinated with HPV vaccine across the United Kingdom. Through the Yellow Card Scheme,
341 reports included a suspected psychiatric event. The detailed medical history is
not always provided in Yellow Card reports. Evaluation of such reports does not indicate
a causal association with the HPV vaccine. In July 2015, the CHM thoroughly reviewed
the safety of HPV vaccines and concluded that the evidence does not support a link
between HPV vaccination and the development of chronic illnesses.</p>
|
|
